Stem Cell Training, a subsidiary of Global Stem Cells Group, has announced that Juan Romero, M.D., a director and founding member of Anti-Aging Cosmetic Laser in Melbourne, Australia will host a stem cell training course for physicians Jan. 28, 2016.
MIAMI, Jan. 21, 2016—Global Stem Cells Group subsidiary Stem Cell Training, Inc. has announced plans to conduct Australia’s first ever stem cells harvesting and reintegration course Jan. 28, 2016. Juan Romero, M.D., a director and founding member of Anti-Aging Cosmetic Laser in Melbourne, will host the adipose and bone marrow stem cell training course for physicians.
Romero has been practicing cosmetic surgery since 1998 and has worked in both the public hospital system in Australia and the U.S. while performing his surgical training. More recently he has worked in private practice as a general practitioner in Wantirna and Dandenong, Australia.
A Member of the Cosmetic Physician Society of Australia, Romero regularly attends clinical training courses and meetings, and is responsible for the training of other cosmetic practitioners. He is an accredited injector and official trainer for Allergan. Romero’s expertise includes cosmetic medicine procedures including laser, thermage and lipodissolve.
The Adipose and Bone Marrow Stem Cell Training Course was developed for physicians interested in learning the process of isolating and re-integrating adipose- and bone marrow-derived stem cells through an intensive, hands-on training session. The objective is to arm participating physicians with clinical protocols and state-of-the-art regenerative medicine techniques so that they can bring regenerative medicine therapies to their patients in-office. Bloom will focus the training session on stem cell treatments in orthopedic applications.
Global Stem Cells Group’s Stem Cell Training, Inc. courses have been extended to approximately 35 countries, allowing a global community of physicians to learn how to apply these new stem cell technologies.
For more information, visit the Global Stem Cells Group website, email info(at)stemcelltraining(dot)net, or call 305-224-1858. 
About Global Stem Cell Group:
Global Stem Cells Group is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
About Stem Cell Training, Inc.:
Stem Cell Training, Inc. is a multi-disciplinary company offering coursework and training in 35 cities worldwide. Coursework offered focuses on minimally invasive techniques for harvesting stem cells from adipose tissue, bone marrow and platelet-rich plasma. By equipping physicians with these techniques, the goal is to enable them to return to their practices, better able to apply these techniques in patient treatments.
The company’s training courses are designed to make the best use of stem cell technology available to treat various diseases in a manner that is accessible to everyone. Stem Cell Training, Inc.’s mission is to introduce the promising world of cellular medicine to everyone who can benefit from its application, and to provide high quality, effective and efficient training that complies with the highest medical standards to physicians worldwide.
###

MIAMI, Dec. 22, 2015—Global Stem Cells Group announced the appointment of Daniça Goleš to the position of chief international marketing officer for the biotech company. Goleš, who has served in the same capacity for the GSCG headquarters in Chile since 2014, is a specialist in sociology and coaching with a concentration in medicine and surgery, and has 20 years’ experience in medical marketing, management and strategic communications.

Prior to joining Global Stem Cells Group’s team in Chile, Goleš was the director of strategic communication management in the two largest university hospitals in Chile, leading the department for seven years at the University of Chile and another seven years at the Pontifical Catholic University of Chile.
Goleš developed two private strategic consulting practices for the medical and surgical areas of organ transplant teams, digestive surgery, bariatric, rare diseases, orthopedics and plastic surgery for Chile’s most important advocates.
She was a founding partner of Healthvision Ltd., Coach Pacients SA, and Communication and Medicine Ltd.  Both companies engaged in the management of medical and health content and validating reliable sources for the media, development and production of television programs and developing business models for clinical management. Goleš establshed policy for improved patient information and improved relationships between the organization’s professionals and end users.

Since beginning her training in 2000 on Chile’s first steps in cell therapy, Goleš developed management models for regenerative medicine patients. Next, she completed internships in Germany and Chicago with stem cell development groups. She is a member of the International Society of Cell Therapy and the International Society for Stem Cell Research (ISSR).
In 2012, she received the Robert Wood Johnson Foundation (Johnson & Johnson) Community Health Leaders award, which honors advocates in the health care industry who have made a difference in improving the health and access to care for patients in underserved populations.
Goleš  graduated from the Professional Institute of Santiago and completed her post graduate studies at the  Universidad Alberto Hurtado in Santiago, Chile in 2002 with a diploma in Communications and New Technologies. She subsequently completed her masters degree in Psychology and Coaching at the University of Chile Institute of Communications with concentrations in Clinical Units Top Management, strategic planning at Les Halles, Paris and brand management and Internet Domains at the University of Chile.
“We are very happy that Daniça is bringing her skills to our international efforts at a time when the company is growing exponentially worldwide,” says Global Stem Cells Group CEO Benito Novas. “Danica did a remarkable job for us in Chile, and now we can benefit from her talents at the international level.”
For more information, visit the Global Stem Cells Group website, Email bnovas@stemcellsgroup.com, or call 305-560-5337.
About the Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.
With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

MIAMI, Oct. 5, 2015— Global Stem Cells Group, Inc. has named Stemlab.com founder and prominent plastic surgeon Alfredo Hoyos, M.D. as permanent  head of  the GSCG Faculty. Hoyos has been an active member of the GSCG team since signing on as an exclusive representative for the stem cell leader’s Colombian territory in September, 2014.
The Global Stem Cells Group / Stem Cell Training Faculty consists of a distinguished board of physicians, all experts in stem cell and regenerative medicine. The faculty reviews, updates and makes decision pertaining to the training programs offered through the Stem Cell Training division of Global Stem Cells Group. Faculty members also share the latest hand-on techniques and technologies with physicians, nurses, and other health care professionals through SCT’s instructional stem cell training courses.
Hoyos divides his time between practices in Miami and Bogota, Colombia.
Hoyos earned his medical degree at the University of Rosario and completed his residency in plastic surgery at Rosario – Saint Joseph Hospital in Bogotá, Colombia. He later founded Stemlab to further the development of aesthetic techniques using  stem cell (stromal) derived from adipose tissue.
Stemlab is currently conducting extensive research in regenerative medicine in an effort to establish stem cell treatments that can repair damaged tissue in living organisms, using natural biological mechanisms that are proving useful in auto repair processes on damaged tissue.
Hoyos is the inventor of the High Definition Liposculpture (HDL) and Dynamic Definition at Lipoplasty (4D) techniques as well as other advanced techniques that focus on body contouring.
Author of several scientific articles that discuss innovations and new technologies that work on body contour, Hoyos is also the inventor of proprietary tools and applications of plastic surgery devices.
To learn more, visit the Global Stem Cells Group website, email bnovas@steemcellsgroup.com, or call +1 305 560 5337.
About the Global Stem Cell Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

MIAMI, Sept. 21, 2015—Global Stem Cells Group, in collaboration with medical software company Datamed SA Chile, has announced the plans to launch StemData, the first cloud-based electronic medical record system specifically designed for regenerative medicine practitioners.
The new StemData system will come programmed with the latest point of care regenerative medicine protocols and follow-up procedures to make it easy for stem cell practitioners to document patient progress and gather important data to establish the safety and efficacy of stem cell treatments in an doctor’s office environment. The system app will be marketed exclusively through Global Stem Cells Group and will be provided free of charge to affiliate physicians in the new Stem Cell Center network.

The cloud-based, server-less StemData solution will be accessible via web, iPad, iPhone, Google Glass and Apple Watch. Global Stem Cells Group and Datamed have utilized the development of the latest electronic medical record (EMR) systems to bring intelligent EMR technology to regenerative medicine specialists.
The StemData app will help regenerative medicine physicians increase efficiencies in their medical practices while improving both treatment and business outcomes. The app will intuitively adapt to each individual practitioner’s unique practice preferences.
To learn more, visit the Global Stem Cells Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.
About the Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

Global Stem Cells Group has announce a new alliance with Santiago, Chile-based Cellus, a stem cell company dedicated to research, development and commercialization of therapeutic services and custom biotech products in regenerative medicine

MIAMI, FLA. (PRWEB) SEPTEMBER 28, 2015

Global Stem Cells Group has announced a new strategic alliance with Cellus to promote clinical research, physician training and patient treatment in Chile. Based in Santiago, Chile, Cellus is a stem cell company and full GMP lab dedicated to research, development and commercialization of therapeutic services and custom biotech products in the field of regenerative medicine.

Cellus’s state of the art medical facility, located at the Santiago Marriot, includes conference rooms with views to its cell culture lab and a full, cutting edge operating room for performing stem cell procedures. Cellus is managed by a multi-disciplinary team with extensive clinical experience and biopharmaceutical production, operating under the highest standards and international requirements for quality and safety. Cellus is continuously working to develop effective and innovative regenerative medicine solutions using autologous cellular therapies and biological products obtained from and administered to each individual patient.

“We are very pleased about our new alliance with Global Stem Cells Group,” says Cellus Commercial Manager Carlos Girardi. “We plan to leverage this alliance to further our clinical research, and to boost physician training here in Chile.

“This is a great opportunity to prove how valuable a collaboration between two international stem cell forces like Cellus and GSCG can be.”

Global Stem Cells Group, Chile CEO Enrique Testart agrees, adding that the new collaboration between the two companies will help GSCG establish itself as the leader in regenerative medicine therapies in Chile.

“Both Cellus and Global Stem Cells Group bring extraordinary insight, knowledge and experience in stem cell medicine to the table, and together we can accomplish great things,” Testart says. “I’m very excited to work with the excellent team at Cellus.”

The collaboration is part of Global Stem Cells Group’s push to highlight Chile’s appeal as a destination for patients seeking stem cell therapies for a variety of conditions, and as part of its ongoing commitment to expand the reach of stem cell treatments throughout Latin America.

To learn more, visit the Global Stem Cells Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

About Cellus:

Cellus is dedicated to research, development and commercialization of therapeutic services and custom biotech products in the field of regenerative medicine. Their multidisciplinary team of stem cell experts focus on the prevention and reversal of impairment in the skin of patients with traumatic injuries, skin diseases or symptoms of aging.

Their state-of-the-art facility in Santiago features a full laboratory and showcases the company’s extensive clinical expertise and biopharmaceutical production capabilities.

###

Global Stem Cells Group announces a new alliance with Santiago, Chile-based VidaCel Laboratories, Latin America’s oldest and largest cryopreserved umbilical cord blood bank.

MIAMI (PRWEB) SEPTEMBER 25, 2015

Global Stem Cells Group has announced a new collaboration with Santiago, Chile-based VidaCell Laboratories, Latin America’s oldest and largest cryopreserved umbilical cord cell bank. The alliance is focused on creating new protocols for cryopreservation of cord blood, cord tissue, adipose tissue and dental pulp stem cells, and the culture and expansion of cell colonies.

The GSCG / VidaCel alliance will provide both companies broader access to the newest stem cell technologies for application in new territories. With Global Stem Cells Group’s growing presence in Latin America, the collaboration with VidaCel will eliminate the potential for significant delays in collecting and processing stem cells, which can result in a loss of cell viability.

According to Global Stem Cells Group CEO Benito Novas, the rules of the National Program for Bone Marrow Donation in the U.S. provide the guidelines used by VidaCel for processing cord blood cells within 24 hours.

“VidaCel’s location in Chile guarantees immediate availability of cells,” Novas says.
“Their process of collecting, processing and preserving stem cells is performed under the strictest standards of biosecurity, and designed to better safeguard the material over a lifetime, which makes them a perfect collaborator for Global Stem Cells Group.”

Tissue stem cells, or mesenchymal stem cells, harvested from umbilical cord blood and tissue, can differentiate and generate cells of different tissues, mainly connective or supportive, such as bone, cartilage or muscle. Studies show that they can also participate in the process of tissue regeneration through other mechanisms such as immunosuppression, production factors and cell stimulators present in tissue or a damaged organ. Tissue stem cells also have characteristics that allow them to adapt fairly easily to the action of the immune system of an individual, which is why they are essential for use in allogeneic procedures in which immunologic compatibility is a factor.

Stem cells harvested from adipose tissue can differentiate into bone, cartilage, tendon and muscle, and can strengthen defensive and regenerative function. Adipose stem cells are found in adipose (fat) tissue.
Stem cells harvested from dental pulp can also differentiate into bone, cartilage, tendon and muscle to reinforce their defensive and regenerative function. These cells are found in the teeth.

Over time, the body’s stem cells succumb to environmental insults, a common occurrence in the aging process. Cryopreserving stem cells from young patients at an early stage means preserving their maximum viability.
To learn more, visit the Global Stem Cells Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

About VidaCel:

Established in 2004,VidaCel® is the largest cell blood bank in Latin America, known for its cryopreservation of umbilical cord stem cells, adipose tissue stem cells and dental pulp stem cells. VidaCel follows the rules of the National Program for Bone Marrow Donation’s. U.S. entity, which also provides guidelines concerning Cord Blood Banks.

Located in Santiago, Chile, VidaCel is the first and only public access stem cell bank in Chile, and guarantees immediate availability of cells. VidaCel is committed to the advancement of new technologies and treatments, in conjunction with leading universities. VidaCel is accredited by the Ministry of Health and the Public Health Institute, and all processes are certified by the international quality standard ISO-9001.

Global Stem Cells Group will launch two new versions of its “Diplomat in Cell Therapy and Tissue Engineering” post-graduate program. The program will be offered in Chile in 2016

MIAMI (PRWEB) SEPTEMBER 29, 2015

Stem Cell Training, Inc., a division of the Global Stem Cells Group, has announced plans to launch two new editions of the post-graduate diploma program, “Diplomat in Cell Therapy and Tissue Engineering.” The first of its kind worldwide, the program is designed for physicians and qualified practitioners to bring stem cell therapies into the doctor’s office to treat patients.

The program focuses on advances in cell biology that emerged in the late 20th and early 21st centuries to give rise to stem cell therapies—a new form of medical treatment in which cells and tissues are used as healing elements, not only to supplement or replace deficient cells, but to induce regeneration and restoration of a lost biological order during the development of a disease or injury.

According to Global Stem Cells Group CEO Benito Novas, cell therapy is becoming the foundation of future medicine. For that reason, making stem cell sciences and treatment courses available to physicians and qualified medical practitioners is fundamental to the future of medicine. “Diplomat in Cell Therapy and Tissue Engineering” offers professionals invaluable lessons in the new art of healing, as well as the scientific and practical methodologies concerning this new discipline.

The aim of this postgraduate course is to train high-achieving, academic level professionals in cell therapy and tissue engineering to use in different areas of medicine and dentistry.

Course topics include:

• Somatic cell therapy and tissue engineering and associated bioethical issues.
• Cell Structure and functions, cell and tissue growth, cell differentiation and genetic and epigenetic regulation.
• Interaction of cells with other cells and extracellular matrix, humeral microenvironment.
• Development of cell interactions during embryogenesis, tissue regeneration, tissue repair and cancer.
• Immunology: Humeral and cellular immunity, innate and acquired immunity, interactions, effector function, immune tolerance, trophic and reconstructive function.
• Biology of embryo development, and normal and pathological tissue repair: overview of embryonic and fetal post-natal development, genetic and epigenetic factors that influence growth, embryonic fetal and postnatal development, maintenance and repair process of cells, tissue and organs, and genetic and epigenetic factors that interact and influence these processes.
• Identification of certain cellular therapies that repair or correct defects.
• Method of production, processing and application of biological drugs for Cell Therapy and Tissue Engineering.
• Sources of the cells used in cell therapy. Enforcement of cell techniques. Complex manipulation processes, GMP Standards. Cell processing laboratories. The Biosafety and quality of cellular products: Identity, Purity, Power, Security.
• Cell administration. Implant techniques. Evaluating the results of cell therapy.
• Layout of clinical trials.

Educational strategies will be taught in theory and in practical hands-on classes, during which students can raise questions and work on problem solving. Practical work will be first carried out on animals; laboratory practices will be taught, followed by demonstration of therapies on humans.

Students will take a written exam on the last day; A score of 7 or better out of 10 is required to pass. Evaluations will be complemented with the development of a thesis, to be graded as pass or fail and must be supported with an oral examination.

To learn more, visit the Stem Cells Training website, the Global Stem Cells Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

About Stem Cell Training, Inc.:

Stem Cell Training, Inc. is a multi-disciplinary company offering coursework and training in 35 cities worldwide. Coursework offered focuses on minimally invasive techniques for harvesting stem cells from adipose tissue, bone marrow and platelet-rich plasma. By equipping physicians with these techniques, the goal is to enable them to return to their practices, better able to apply these techniques in patient treatments.

The company’s training courses are designed to make the best use of stem cell technology available to treat various diseases in a manner that is accessible to everyone. Stem Cell Training, Inc.’s mission is to introduce the promising world of cellular medicine to everyone who can benefit from its application, and to provide high quality, effective and efficient training that complies with the highest medical standards to physicians worldwide.